A retrospective analysis of different modalities for treatment of primary orbital non-Hodgkin's lymphomas

被引:79
作者
Esik, O [1 ]
Ikeda, H [1 ]
Mukai, K [1 ]
Kaneko, A [1 ]
机构
[1] NATL CANC CTR,CHUO KU,TOKYO 104,JAPAN
关键词
non-Hodgkin's lymphoma; orbit; radiotherapy; surgery; chemotherapy; complication;
D O I
10.1016/0167-8140(95)01658-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have reviewed 37 patients with primary orbital lymphoma, using the Ann Arbor criteria and the Working Formulation and its modification. Thirty-one patients had stage I disease, four stage II, one stage III and one stage IV. The male to Female ratio was 2.7:1. There were 34 low-grade tumours (including 24 mantle zone) and three intermediate-grade. Patients were divided into three groups according to their primary treatment. Group 1: radiotherapy (17 cases); Group 2: surgery alone (13 cases); Group 3: chemotherapy (seven cases). Patients were followed up from 5 months to 24.3 years, with a mean and median of 7.6 and 6.2 years, respectively. The BMDP software package was used for survival estimation (Kaplan-Meier) and determination of prognostic variable (univariate Cox regression). Local relapse-free survival at 10 years was 100% in Group 1, 0% in Group 2 and 42% in Group 3 with a statistically significant difference (p < 0.01) in favour of radiotherapy. Statistically significant good prognostic features were: complete remission (CR) in response to initial treatment, primary radiotherapy and older age. For stage I cases, there was no difference in distant relapse-free survival in the three groups. The overall cause-specific survival for stage I patients at 10 years was 100% for each group and at 20 years was 100, 67 and 0% for Groups 1, 2 and 3. The difference between the primary radiotherapy and chemotherapy-treated groups was significant at the p = 0.08 level. Statistically significant prognostic factors were early stage, low-grade histology and primary radiotherapy. In one patient, ptosis and diplopia appeared after surgery. One case of glaucoma required enucleation, one patient suffered severe dry eye syndrome. All patients (11/11) in whom the lens received direct radiation developed cataracts of different degrees if follow-up was long enough. Cataract formation was prevented by adequate lens shielding. One patient in CR from a stage I low-grade tumour died from chemotherapy-induced marrow aplasia. Primary orbital lymphoma is an indolent, usually stage I disease, showing low to intermediate-grade histology. After biopsy the best treatment is 30 (low-grade) to 40 Gy (intermediate-grade) carefully planned, lens-sparing megavoltage radiation without adjuvant chemotherapy.
引用
收藏
页码:13 / 18
页数:6
相关论文
共 23 条
[1]  
[Anonymous], CANCER
[2]   OCULAR MORBIDITY AFTER RADIOTHERAPY OF ORBITAL AND CONJUNCTIVAL LYMPHOMA [J].
BESSELL, EM ;
HENK, JM ;
WHITELOCKE, RAF ;
WRIGHT, JE .
EYE-TRANSACTIONS OF THE OPHTHALMOLOGICAL SOCIETIES OF THE UNITED KINGDOM, 1987, 1 :90-96
[3]  
CALLE R, 1975, EYEEAR NOSE THROAT M, V54, P141
[4]  
CARBONE PP, 1971, CANCER RES, V31, P1860
[5]   CONJUNCTIVAL LYMPHOMA - RESULTS AND TREATMENT WITH A SINGLE ANTERIOR ELECTRON FIELD - A LENS SPARING APPROACH [J].
DUNBAR, SF ;
LINGGOOD, RM ;
DOPPKE, KP ;
DUBY, A ;
WANG, CC .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (02) :249-257
[6]   LYMPHORETICULAR TUMORS OF THE ORBIT [J].
FITZPATRICK, PJ ;
MACKO, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1984, 10 (03) :333-340
[7]   RADIOTHERAPY OF PRIMARY LYMPHOMA OF ORBIT [J].
FOSTER, SC ;
WILSON, CS ;
TRETTER, PK .
AMERICAN JOURNAL OF ROENTGENOLOGY RADIUM THERAPY AND NUCLEAR MEDICINE, 1971, 111 (02) :343-&
[8]   RADIATION-DOSE TO THE LENS AND CATARACT FORMATION [J].
HENK, JM ;
WHITELOCKE, RAF ;
WARRINGTON, AP ;
BESSELL, EM .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 25 (05) :815-820
[9]  
HORNING SJ, 1993, SEMIN ONCOL, V20, P75
[10]   TREATMENT OF INDOLENT NON-HODGKINS-LYMPHOMA LOCALIZED IN THE HEAD AND NECK [J].
IKEDA, H ;
INOUE, T ;
TESHIMA, T ;
MURAYAMA, S ;
KOZUKA, T ;
AOZASA, K .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (01) :72-76